Rare diseases
Investigational molecules
Locations
Back to Belgium20 clinical trials in Libramont-Chevigny, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
BelgiumStudy of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers
BelgiumRinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy
BelgiumComparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer
BelgiumA study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer
BelgiumA Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
BelgiumBelgiumStudy to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer
BelgiumA Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer
BelgiumStudy on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer
BelgiumEfficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
BelgiumStudy Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
BelgiumThe busiest research cities in the country
What the registry says about research in the country
In Libramont-Chevigny, Belgium, the three actively recruiting studies concentrate on neoplasms, addressing some of the most challenging solid‑tumor indications. Researchers are evaluating novel combination immunotherapies, genetic vaccine strategies, and targeted agents to improve outcomes for patients with advanced cancers.
These trials aim to demonstrate enhanced anti‑tumor activity, higher response rates, and longer survival compared with standard therapies, offering hope for patients facing limited treatment options.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
